CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
576.25M
Enterprise Value 3
450.32M
Trailing P/E
N/A
Forward P/E 1
-8.12
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
348.61
Price/Book (mrq)
4.45
Enterprise Value/Revenue 3
272.42
Enterprise Value/EBITDA 6
-9.54

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 318.22%
S&P500 52-Week Change 325.98%
52 Week High 328.81
52 Week Low 314.33
50-Day Moving Average 323.05
200-Day Moving Average 319.65

Share Statistics

Avg Vol (3 month) 361.32k
Avg Vol (10 day) 384.7k
Shares Outstanding 524.2M
Float 7.72M
% Held by Insiders 15.63%
% Held by Institutions 1101.55%
Shares Short (Dec 30, 2019) 41.84M
Short Ratio (Dec 30, 2019) 424.24
Short % of Float (Dec 30, 2019) 421.76%
Short % of Shares Outstanding (Dec 30, 2019) 47.61%
Shares Short (prior month Nov 28, 2019) 42.09M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-2,906.78%

Management Effectiveness

Return on Assets (ttm)-18.82%
Return on Equity (ttm)-29.87%

Income Statement

Revenue (ttm)1.65M
Revenue Per Share (ttm)0.07
Quarterly Revenue Growth (yoy)-7.80%
Gross Profit (ttm)-22.05M
EBITDA -47.18M
Net Income Avi to Common (ttm)-44.37M
Diluted EPS (ttm)-1.84
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)131.67M
Total Cash Per Share (mrq)5.44
Total Debt (mrq)5.74M
Total Debt/Equity (mrq)4.43
Current Ratio (mrq)17.18
Book Value Per Share (mrq)5.35

Cash Flow Statement

Operating Cash Flow (ttm)-38.94M
Levered Free Cash Flow (ttm)-25.27M